Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male

NCT00651326 2023-08-04

DART

Phase 3 Terminated

48 enrolled

Genitourinary

Prostatic Neoplasms

NCT01619813 2023-08-04

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

85 enrolled

Genitourinary

Prostatic Neoplasms

NCT00027859 2023-06-15

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Phase 3 Completed

Genitourinary

Prostatic Neoplasms

NCT00288080 2022-06-21

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Phase 3 Completed

612 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT00134056 2021-10-27

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Phase 3 Completed

1,038 enrolled 20 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00653848 2021-03-25

AdRad

Phase 3 Unknown

378 enrolled

Genitourinary

Prostatic Neoplasms

NCT01160705 2020-11-17

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Completed

73 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00030654 2020-10-22

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Phase 3 Completed

21 enrolled

Genitourinary

Prostatic Neoplasms

NCT00528866 2019-04-24

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Phase 2 Completed

80 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT01603420 2016-03-14

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

Phase 2/3 Terminated

2 enrolled 8 charts

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00004001 2014-02-25

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 3 Completed

770 enrolled

Genitourinary

Prostatic Neoplasms

NCT00085228 2012-09-24

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Phase 2 Completed

116 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

OPTION-DDR

TRIPLE-SWITCH

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

DART

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

AdRad

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate